Anavex Life Sciences
(NASDAQ) AVXL
Anavex Life Sciences Financials at a Glance
Market Cap
$231.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$39.95M
EPS (TTM)
-$0.46
P/E Ratio
-5.38
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Price
$2.50
Volume
749,693.672
Open
$2.70
Price
$2.50
Volume
749,693.672
Open
$2.70
Previous Close
$2.50
Daily Range
$2.43 - $2.71
52-Week Range
$2.41 - $13.99
Estimated Earnings Date
Jul 9, 2026
Dividend
$0.00
Beta (Volatility)
1.73 (High)
Price
$2.50
Volume
749,693.672
Open
$2.70
Previous Close
$2.50
Daily Range
$2.43 - $2.71
52-Week Range
$2.41 - $13.99
Estimated Earnings Date
Jul 9, 2026
AVXL News
Is Anavex Life Sciences a Buy?
AVXL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Anavex Life Sciences
Industry
Biotechnology
Sector
Health CareEmployees
34
CEO
Christopher U. Missling, PhD, MBA
Website
www.anavex.comHeadquarters
New York City, NY 10019, US
AVXL Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-38.76%
Return on Capital
-54.19%
Return on Assets
-30.04%
Earnings Yield
-18.59%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$231.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
92.67M
Volume
749.69K
Avg. Volume
1.19M
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$44.60M
EBITDA
-$38.87M
Operating Cash Flow
-$34.08M
Capital Expenditure
$0.00
Free Cash Flow
-$34.08M
Cash & ST Invst.
$131.75M
Total Debt
$0.00
Anavex Life Sciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$231.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$5.52M
N/A
Employees
42
N/A
Net Income
-$5.68M
+53.1%
EBITDA
-$5.66M
+58.3%
Quarterly Fundamentals
Total Cash
$131.75M
+9.1%
Total Debt
$0.00
N/A
Accounts Receivable
$844.00K
-67.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-30.04%
N/A
Return on Invested Capital
-35.22%
N/A
Free Cash Flow
-$7.15M
+41.0%
Operating Cash Flow
-$7.15M
+41.0%